Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Jan;7(1):71-7.
doi: 10.1007/s11910-007-0024-4.

Acid alpha-glucosidase deficiency (Pompe disease)

Affiliations
Review

Acid alpha-glucosidase deficiency (Pompe disease)

Tokiko Fukuda et al. Curr Neurol Neurosci Rep. 2007 Jan.

Abstract

The development and recent approval of recombinant acid alpha-glucosidase for enzyme replacement therapy have been major milestones in Pompe disease research. Acid alpha-glucosidase is the enzyme responsible for degradation of glycogen polymers to glucose in the acidic milieu of the lysosomes. Cardiac and skeletal muscles are the two major tissues affected by the accumulation of glycogen within the lysosomes. Both cardiomyopathy and skeletal muscle myopathy are observed in patients with complete enzyme deficiency; this form of the disease is fatal within the first year of life. Skeletal muscle myopathy eventually leading to respiratory insufficiency is the predominant manifestation of partial enzyme deficiency. The recombinant enzyme alglucosidase alfa is the first drug ever approved for this devastating disorder. This review discusses the benefits and the shortcomings of the new therapy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Pediatr. 2004 May;144(5 Suppl):S35-43 - PubMed
    1. Am J Med Genet. 1998 Aug 27;79(1):69-72 - PubMed
    1. J Neurol. 2005 Aug;252(8):875-84 - PubMed
    1. Clin Chem. 2000 Sep;46(9):1318-25 - PubMed
    1. Annu Rev Biochem. 1992;61:307-30 - PubMed

MeSH terms